{"id":4581,"date":"2025-03-31T18:12:13","date_gmt":"2025-03-31T18:12:13","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/nevirapine-txt\/"},"modified":"2025-03-31T18:12:13","modified_gmt":"2025-03-31T18:12:13","slug":"nevirapine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/nevirapine-txt\/","title":{"rendered":"nevirapine.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nNon-nucleoside reverse transcriptase inhibitor:Treatment of progressive or advanced HIV infection in combination with at least two other antivirals

DOSE IN NORMAL RENAL FUNCTION <\/H3>200 mg daily, increasing to twice daily after 14 days if tolerated

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :266.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <3<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.12\u20131.3<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :45 (single dose) 25\u201330 (multiple dosing)\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antibacterials: concentration decreased by rifampicin \u2013 avoid concomitant use; possibly increased rifabutin concentration\n
  • Anticoagulants: may increase or reduce effect of warfarin\n
  • Antidepressants: concentration reduced by St John\u2019s wort \u2013 avoid concomitant use\n
  • Antifungals: concentration of ketoconazole reduced \u2013 avoid concomitant use; concentration increased by fluconazole; possibly reduced caspofungin concentration \u2013 may need to increase caspofungin dose\n
  • Antipsychotics: possibly reduced aripiprazole concentration \u2013 increase aripiprazole dose\n
  • Antivirals: concentration of indinavir and efavirenz reduced and possibly amprenavir, lopinavir and atazanavir \u2013 avoid concomitant use with atazanavirOestrogens and progestogens: accelerated metabolism (reduced contraceptive effect)

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Little data available on the use of nevirapine in renal failure, but need for dose adjustment is unlikely due to nevirapine being predominantly metabolised in the liver, and the inactive metabolites excreted in the urine. Use with cautionThere was a preliminary study of haemodialysis patients which showed that a normal dose was not associated with increased side effects.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Non-nucleoside reverse transcriptase inhibitor:Treatment of progressive or advanced<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4581","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4581"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4581\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}